The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...

A study of Boston Scientific’s Farapulse pulsed field ablation system met safety and efficacy objectives in people with persistent atrial fibrillation (AFib), an irregular heart rhythm that lasts more ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A new study suggests that certain substances in the blood may help identify people with a type of irregular heartbeat called ...

(MENAFN- GlobeNewsWire - Nasdaq) The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD 27 billion in 2025 to USD 62.64 billion ...